Clinical, multicenter, single-arm, with a scheme of treatment with low doses of Bortezomib / Melphalan / Prednisone (Velcade) (MPV) in patients with multiple myeloma (MM) newly diagnosed symptomatic> = 75 years.

Trial Profile

Clinical, multicenter, single-arm, with a scheme of treatment with low doses of Bortezomib / Melphalan / Prednisone (Velcade) (MPV) in patients with multiple myeloma (MM) newly diagnosed symptomatic> = 75 years.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Velcadito
  • Most Recent Events

    • 06 Dec 2016 Results (n=26) of a retrospective analysis in newly diagnosed MM patients not eligible to transplant, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 27 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top